After looking into the case, officials discovered that a coding error prevented the radiology report, which contained critical findings, from ever being sent to the referring provider.

Acoramidis, a selective transthyretin stabilizer being sold under the brand name Attruby, is now the second ATTR-CM medication to gain FDA approval.

A jury found Healthcare Associates of Texas guilty of knowingly submitting tens of thousands of fraudulent claims to Medicare, costing the government more than $2.8 million. 

According to an analysis from the Commonwealth Fund, millions of patients are skipping necessary care and struggling to pay mounting medical debt. 

Medtronic designed its new Smart MDI system to provide real-time insights to users on multiple daily injection therapy.

TAVR is a go-to treatment for symptomatic severe aortic stenosis in much of the world, thanks in large part to the hard work of research teams that never stop looking for new, innovative ways to make the technology more effective.

TAVR procedures have surged more than 30% since 2020, with more than 107,000 patients receiving a new prosthetic valve in 2023 alone. As this trend continues, it’s increasingly important that cardiologists consider the long-term impact on future coronary interventions patients may need.  

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

Cardiovascular Business spoke with cardiologist Daniel Judge, MD, about the long-term benefits of acoramidis, a new drug therapy that just received FDA approval to treat transthyretin amyloid cardiomyopathy.

An influential industry group, AdvaMed, really likes President-Elect Trump’s choice of Dr. Oz for CMS administrator.